Safety and efficacy of azacitidine in myelodysplastic syndromes
نویسندگان
چکیده
PURPOSE The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are reviewed. SUMMARY Azacitidine is the first drug FDA-approved for the treatment of myelodysplastic syndromes that has demonstrated improvements in overall survival and delaying time to progression to acute myelogenous leukemia. The recommended dosage of azacitidine is 75 mg/m(2) daily for 7 days, with different treatment schedules validated. It appears to be well tolerated, with the most common adverse effects being myelosuppression. Several other off-label recommendations were also analyzed. CONCLUSION Azacitidine is the first DNA hypomethylating agent approved by FDA for the treatment of myelodysplastic syndromes with demonstrated efficacy.
منابع مشابه
Azacitidine for the treatment of myelodysplastic syndromes (MDS).pub
Azacitidine is a pyrimidine nucleoside analogue with multiple mechanisms involved in its antineoplastic action. There is evidence that RNA metabolism is the primary target of this antimetabolite, although its inhibition of DNA methylation has been proposed as the main effect responsible for its clinical efficacy in myelodysplastic syndromes. In patients with myelodysplastic syndromes (MDS), aza...
متن کاملPhase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.
Lenalidomide and azacitidine each have activity in myelodysplastic syndromes (MDS) patients, where both microenvironment and cell-regulatory mechanisms contribute to disease pathogenesis. The objective of this multicenter, phase 2 expansion trial was to determine the efficacy and safety of combination therapy with azacitidine (75 mg/m(2)/d for 5 days) and lenalidomide (10 mg/d for 21 days; 28-d...
متن کاملAn update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes
Myelodysplastic syndromes (MDS) are clonal bone marrow malignancies characterized by peripheral cytopenias and dysplastic changes in the bone marrow with various clinical features. Patients with MDS, in particular those with intermediate-2 (Int-2) and high-risk disease, have a poor prognosis. The mainstay of treatment includes cytoxic chemotherapy and supportive care. Over the last decade, prom...
متن کاملAzacitidine in outpatient treatment – single center experience
AIM OF THE STUDY Azacitidine is a hypomethylating agent which is used in the treatment of myelodysplastic syndromes, acute myeloid leukemia and chronic myelomonocytic leukemia. Because of good tolerance to the drug, azacitidine can be administered both during hospitalization and in an outpatient setting. The aim of our retrospective analysis was to assess the efficacy of azacitidine treatment i...
متن کاملEfficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
BACKGROUND Drug treatments for patients with high-risk myelodysplastic syndromes provide no survival advantage. In this trial, we aimed to assess the effect of azacitidine on overall survival compared with the three commonest conventional care regimens. METHODS In a phase III, international, multicentre, controlled, parallel-group, open-label trial, patients with higher-risk myelodysplastic s...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 4 شماره
صفحات -
تاریخ انتشار 2010